Research Analysts’ Weekly Ratings Changes for Integra LifeSciences (IART)

Integra LifeSciences (NASDAQ: IART) recently received a number of ratings updates from brokerages and research firms:

• 10/31/2026 – Integra LifeSciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/27/2026 – Integra LifeSciences was given a new $14.00 price target by UBS Group. They now have a “neutral” rating on the stock.
• 10/26/2026 – Integra LifeSciences was upgraded by Weiss Ratings from “sell (e+)” to “sell (d+)”.
• 10/26/2026 – Integra LifeSciences was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/23/2026 – Integra LifeSciences was given a new $13.00 price target by Truist Financial. They now have a “hold” rating on the stock.
• 10/22/2026 – Integra LifeSciences had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $14.00 price target on the stock, down from $15.00.
• 10/22/2026 – Integra LifeSciences was given a new $13.00 price target by Wells Fargo & Company. They now have an “equal weight” rating on the stock.
• 10/22/2026 – Integra LifeSciences had its “outperform” rating reaffirmed by Citigroup.
• 10/22/2026 – Integra LifeSciences had its price target lowered by Citigroup from $15.00 to $14.00. They now have a “neutral” rating on the stock.
• 10/22/2026 – Integra LifeSciences had its price target lowered by Citizens Jmp from $25.00 to $22.00. They now have a “market outperform” rating on the stock.
• 10/22/2026 – Integra LifeSciences had its price target lowered by JPMorgan Chase & Co. from $17.00 to $14.00. They now have an “underweight” rating on the stock.
• 10/14/2026 – Integra LifeSciences had its price target lowered by Truist Financial from $19.00 to $15.00. They now have a “hold” rating on the stock.
• 10/5/2026 – Integra LifeSciences had its “neutral” rating reaffirmed by Citigroup. They now have a $15.00 price target on the stock, down from $19.00.
• 10/5/2026 – Integra LifeSciences had its price target lowered by BMO Capital Markets from $18.00 to $15.00. They now have a “market perform” rating on the stock.
• 10/3/2026 – Integra LifeSciences was given a new $15.00 price target by Wells Fargo & Company.
• 10/3/2026 – Integra LifeSciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/2/2026 – Integra LifeSciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/1/2026 – Integra LifeSciences was upgraded by Truist Financial to “hold”.

Integra LifeSciences Stock Performance

IART stock opened at $14.77 on Thursday. The company has a 50 day moving average price of $14.41 and a 200 day moving average price of $14.16. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21. The stock has a market capitalization of $1.15 billion, a PE ratio of 86.88, a price-to-earnings-growth ratio of 1.03 and a beta of 1.28.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. The firm had revenue of $411.18 million for the quarter, compared to analyst estimates of $413.16 million. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. During the same period last year, the company earned ($0.07) EPS. Analysts forecast that Integra LifeSciences Holdings Corporation will post 2.34 EPS for the current year.

Integra LifeSciences is a medical technology company that develops products for neurosurgery, surgical care and tissue repair. Its offerings include devices and instruments used in cranial surgery, neuromonitoring and wound reconstruction, as well as materials designed to support the repair or regeneration of tissue. The company’s product portfolio includes dural repair products, cranial stabilization systems, surgical instruments and dermal regeneration products. Integra serves hospitals, surgeons and other healthcare providers in the United States and international markets.